Availability can vary, and a specific formulation is not guaranteed
In addition to these widely used AOMs, Exenatide, one of the earliest GLP-1 RAs approved by the FDA and EMA for T2DM management, is not indicated for weight management but remains clinically relevant, particularly in older adults with comorbid obesity and T2DM, given its long-term clinical experience and established tolerability profile [26,27,28]
The PeptideVite supplement has emerged as an effective way to alleviate these symptoms making treatment more tolerable for patients who are sensitive to these medications
The glutathione patch is another excellent option
The FDA has flagged emideltide/DSIP in a compounding safety-risk context because of insufficient safety information and concerns involving peptide impurities and immunogenicity, while existing human studies are too small and short-term to reliably assess long-term adverse effects